Qatar's Ministry of Public Health (MOPH), through its Pharmacy and Drug Control Department, issued Circular No. PDC/2026/31 on August 25, 2026, prohibiting the handling, distribution, use and promotion of unlicensed peptides. The instrument, published on the MOPH announcements page, finalises a placeholder title into a binding prohibition that reaches every peptide product placed on the Qatari market without a valid MOPH marketing authorisation.
For pharmaceutical marketing authorisation holders, importers, distributors, pharmacies and the weight-loss and cosmetic clinics that have expanded with the global GLP-1 and peptide therapeutics boom, the circular converts a standing licensing expectation into an explicit, named prohibition with immediate effect.
What does the prohibition cover?
The circular prohibits four activities in relation to unlicensed peptides: their handling, distribution, use and promotion. "Unlicensed" means any peptide product that has not been registered or granted a marketing authorisation by the MOPH Pharmacy and Drug Control Department under Qatar's Pharmacy Law, Law No. 3 of 1983, the cornerstone statute governing drug registration, dispensing and pharmacy practice in the country.
The scope is not confined to a single molecule or brand. Read against the GLP-1 receptor agonist expansion and the wider peptide market, it captures compounded, imported or repackaged peptide preparations, including weight-management and aesthetic products, that circulate without the authorisation the department requires for any medicine placed on the Qatari market. A product is in scope the moment it lacks that authorisation, regardless of how it entered the supply chain.
Who must act, and what must they verify?
Every actor that touches a peptide product in Qatar must now confirm that it carries a valid MOPH authorisation and stop the four prohibited activities where it does not. The table maps the obligations to the exposed groups.
| Actor | Required action | Exposure if non-compliant |
|---|---|---|
| Marketing authorisation holders and importers | Audit the registration status of every peptide product; halt imports of unlicensed stock at the border | Seizure of goods, import refusal, authorisation action |
| Distributors and pharmacies | Remove unlicensed peptide stock; verify supplier authorisation before procurement | Stock seizure, pharmacy licence action |
| Weight-loss and cosmetic clinics | Stop dispensing or promoting unlicensed peptides, including compounded GLP-1 preparations; source only licensed product | Licence action, patient-safety liability |
Verification means checking each peptide against the Pharmacy and Drug Control Department's own registration record, not a supplier's certificate of analysis or a foreign approval. A product registered in another jurisdiction is not exempt from the MOPH authorisation requirement, because the department holds the national marketing authorisation for any medicine placed on the Qatari market, so a valid Qatari licence is the only compliance proof that counts.
What enforcement power does Law 3/1983 give MOPH?
Law 3 of 1983 vests the MOPH Pharmacy and Drug Control Department with authority over drug registration, import control, pricing and pharmacy licensing, and the circular is the department's instrument for enforcing those existing duties against unlicensed peptide handling. Non-compliance carries the sanctions the Pharmacy Law provides for unlicensed medicine activity: seizure of the products, administrative penalties and action against the establishment's licence.
Because the circular clarifies duties the Pharmacy Law already imposes, the obligation is not contingent on a future effective date. Compliance is expected from the moment a product is placed on the market, and the August 25, 2026 announcement is the signal to verify portfolios immediately rather than await further guidance. Continuous, per-jurisdiction regulatory monitoring surfaces a change like this the moment the competent authority publishes it.
Take advantage of this real-time watch
Run a peptide portfolio audit against the MOPH register, flag every product without a current authorisation, and pull unlicensed stock from distribution and clinic formularies. Brief procurement and clinic teams that compounded or imported peptide preparations, however labelled, fall in scope, and document the verification for inspection. Track the Pharmacy and Drug Control Department announcements channel for any follow-up circular that names specific substances or deadlines. Obsidian follows Qatar's pharmaceutical rulemaking as part of its per-jurisdiction coverage.
